VectivBio (VECT) Competitors $16.85 0.00 (0.00%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VECT vs. HCM, XENE, MIRM, IBRX, OGN, VCEL, APLS, ARWR, AAPG, and DNLIShould you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), ImmunityBio (IBRX), Organon & Co. (OGN), Vericel (VCEL), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Ascentage Pharma Group International (AAPG), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. VectivBio vs. HUTCHMED Xenon Pharmaceuticals Mirum Pharmaceuticals ImmunityBio Organon & Co. Vericel Apellis Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International Denali Therapeutics HUTCHMED (NASDAQ:HCM) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment. Which has higher earnings and valuation, HCM or VECT? HUTCHMED has higher revenue and earnings than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M3.66$100.78MN/AN/AVectivBio$27.34M20.97-$93.74MN/AN/A Does the MarketBeat Community prefer HCM or VECT? HUTCHMED received 306 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 66.11% of users gave HUTCHMED an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformHUTCHMEDOutperform Votes31666.11% Underperform Votes16233.89% VectivBioOutperform Votes1043.48% Underperform Votes1356.52% Does the media prefer HCM or VECT? In the previous week, HUTCHMED had 1 more articles in the media than VectivBio. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for VectivBio. HUTCHMED's average media sentiment score of 0.41 beat VectivBio's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media. Company Overall Sentiment HUTCHMED Neutral VectivBio Neutral Which has more risk and volatility, HCM or VECT? HUTCHMED has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Do insiders & institutionals believe in HCM or VECT? 8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is HCM or VECT more profitable? Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A VectivBio N/A N/A N/A Do analysts rate HCM or VECT? HUTCHMED presently has a consensus price target of $19.00, indicating a potential upside of 43.72%. Given HUTCHMED's stronger consensus rating and higher possible upside, equities research analysts plainly believe HUTCHMED is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHUTCHMED beats VectivBio on 10 of the 12 factors compared between the two stocks. Get VectivBio News Delivered to You Automatically Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VECT vs. The Competition Export to ExcelMetricVectivBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.24M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E RatioN/A30.5026.8419.71Price / Sales20.97400.15392.34117.39Price / CashN/A168.6838.2534.62Price / BookN/A3.286.794.50Net Income-$93.74M-$72.17M$3.23B$248.18M7 Day PerformanceN/A2.96%1.53%0.20%1 Month PerformanceN/A3.25%10.06%12.37%1 Year PerformanceN/A-28.29%16.72%7.04% VectivBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeHCMHUTCHMED2.2758 of 5 stars$13.14-5.6%$19.00+44.6%-33.6%$2.29B$630.20M0.001,760Positive NewsGap DownXENEXenon Pharmaceuticals3.2254 of 5 stars$29.60-17.4%$54.80+85.1%-21.9%$2.27B$9.43M-10.50210Positive NewsAnalyst DowngradeHigh Trading VolumeMIRMMirum Pharmaceuticals4.0844 of 5 stars$45.27-0.7%$60.64+33.9%+71.8%$2.24B$379.25M-22.41140Positive NewsAnalyst ForecastAnalyst RevisionIBRXImmunityBio1.8581 of 5 stars$2.51+6.4%$12.19+385.6%-61.1%$2.22B$14.75M-2.73590Analyst UpgradeHigh Trading VolumeOGNOrganon & Co.4.7561 of 5 stars$8.43-3.2%$18.00+113.5%-61.3%$2.19B$6.29B2.5310,000High Trading VolumeVCELVericel2.5561 of 5 stars$43.64+2.3%$60.86+39.5%-20.3%$2.19B$238.54M727.45300Positive NewsAPLSApellis Pharmaceuticals4.1686 of 5 stars$17.28-1.4%$41.37+139.4%-59.1%$2.17B$775.84M-8.51770ARWRArrowhead Pharmaceuticals3.5161 of 5 stars$15.28+9.4%$42.13+175.7%-38.8%$2.10B$2.50M-2.96400Positive NewsAnalyst ForecastGap UpHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$24.04-0.7%N/AN/A$2.09B$980.65M0.00600Positive NewsDNLIDenali Therapeutics4.4182 of 5 stars$14.26-3.6%$33.79+136.9%-31.5%$2.07B$330.53M-5.17430Analyst Forecast Related Companies and Tools Related Companies HCM Alternatives XENE Alternatives MIRM Alternatives IBRX Alternatives OGN Alternatives VCEL Alternatives APLS Alternatives ARWR Alternatives AAPG Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VECT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VECT Stock Free VECT Stock Alerts